لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Broad LM; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Sanger HE; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Mogg AJ; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Colvin EM; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Zwart R; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Evans DA; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Pasqui F; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Sher E; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Wishart GN; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK., Barth VN; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Felder CC; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Goldsmith PJ; Eli Lilly and Company, Lilly Research Centre, Windlesham, Surrey, UK.

المصدر: British journal of pharmacology [Br J Pharmacol] 2019 Jan; Vol. 176 (1), pp. 110-126. Date of Electronic Publication: 2018 Nov 16.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Osteopontin/*agonists , Piperidines/*pharmacology , Receptor, Muscarinic M1/*agonists , Spiro Compounds/*pharmacology, Animals ; CHO Cells ; Cells, Cultured ; Cricetulus ; Male ; Mice ; Mice, Inbred C57BL ; Molecular Structure ; Piperidines/chemistry ; Rats ; Rats, Sprague-Dawley ; Spiro Compounds/chemistry ; Structure-Activity Relationship ; Xenopus

المؤلفون: Raub TJ; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.) raubtj@lilly.com., Wishart GN; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.)., Kulanthaivel P; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.)., Staton BA; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.)., Ajamie RT; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.)., Sawada GA; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.)., Gelbert LM; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.)., Shannon HE; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.)., Sanchez-Martinez C; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.)., De Dios A; Drug Disposition, Lilly Research Laboratories (T.J.R., G.N.W., P.K., B.A.S., R.T.A., G.A.S.), Division of Cancer Research (L.M.G., H.E.S.), and Discovery Chemistry Research and Technologies (A.D.D.), Eli Lilly and Company, Indianapolis, Indiana; Discovery Chemistry Research and Technologies, Eli Lilly and Company, Alcobendas, Madrid, Spain (C.S.-M.); and Covance Laboratories, Greenfield, Indiana (H.E.S.).

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2015 Sep; Vol. 43 (9), pp. 1360-71. Date of Electronic Publication: 2015 Jul 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*pharmacology , Benzimidazoles/*pharmacology , Brain/*drug effects , Brain Neoplasms/*drug therapy , Cyclin-Dependent Kinase 4/*antagonists & inhibitors , Cyclin-Dependent Kinase 6/*antagonists & inhibitors , Glioblastoma/*drug therapy , Piperazines/*pharmacology , Protein Kinase Inhibitors/*pharmacology , Pyridines/*pharmacology, Aminopyridines/administration & dosage ; Aminopyridines/therapeutic use ; Animals ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzimidazoles/administration & dosage ; Benzimidazoles/therapeutic use ; Brain Neoplasms/pathology ; Dacarbazine/administration & dosage ; Dacarbazine/analogs & derivatives ; Dogs ; Female ; Glioblastoma/pathology ; Madin Darby Canine Kidney Cells ; Male ; Mice ; Piperazines/administration & dosage ; Piperazines/therapeutic use ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/administration & dosage ; Pyridines/therapeutic use ; Rats ; Temozolomide ; Xenograft Model Antitumor Assays

المؤلفون: Witkin JM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Overshiner C; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Li X; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Catlow JT; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Wishart GN; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Schober DA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Heinz BA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Nikolayev A; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Tolstikov VV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Anderson WH; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Higgs RE; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Kuo MS; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Felder CC; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom felder_christian@lilly.com jwitkin@lilly.com.

المصدر: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2014 Nov; Vol. 351 (2), pp. 448-56. Date of Electronic Publication: 2014 Sep 03.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antidepressive Agents/*pharmacology , Receptor, Muscarinic M1/*metabolism , Receptor, Muscarinic M2/*metabolism , Scopolamine/*pharmacology, Animals ; Brain/drug effects ; Brain/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout/metabolism ; Motor Activity/drug effects ; Muscarinic Antagonists/pharmacology ; Rats ; Rats, Sprague-Dawley ; Swimming/physiology

المؤلفون: Gelbert LM; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA, de_dios_alfonso@lilly.com., Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A

المصدر: Investigational new drugs [Invest New Drugs] 2014 Oct; Vol. 32 (5), pp. 825-37. Date of Electronic Publication: 2014 Jun 13.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*pharmacology , Antineoplastic Agents/*pharmacology , Benzimidazoles/*pharmacology , Cyclin-Dependent Kinase 4/*antagonists & inhibitors , Cyclin-Dependent Kinase 6/*antagonists & inhibitors , Protein Kinase Inhibitors/*pharmacology, Aminopyridines/therapeutic use ; Animals ; Antineoplastic Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Cell Line, Tumor ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Therapy, Combination ; Female ; G1 Phase Cell Cycle Checkpoints/drug effects ; Humans ; Mice ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Neoplasms/pathology ; Phosphorylation/drug effects ; Protein Kinase Inhibitors/therapeutic use ; Retinoblastoma Protein/antagonists & inhibitors ; Retinoblastoma Protein/metabolism ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays ; Gemcitabine

المؤلفون: Tate SC; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and tate_sonya@network.lilly.com., Cai S; Eli Lilly and Company, Indianapolis, Indiana., Ajamie RT; Eli Lilly and Company, Indianapolis, Indiana., Burke T; Eli Lilly and Company, Indianapolis, Indiana., Beckmann RP; Eli Lilly and Company, Indianapolis, Indiana., Chan EM; Eli Lilly and Company, Indianapolis, Indiana., De Dios A; Eli Lilly and Company, Indianapolis, Indiana., Wishart GN; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and., Gelbert LM; Eli Lilly and Company, Indianapolis, Indiana., Cronier DM; Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Jul 15; Vol. 20 (14), pp. 3763-74. Date of Electronic Publication: 2014 May 21.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*pharmacokinetics , Antineoplastic Agents/*pharmacokinetics , Benzimidazoles/*pharmacokinetics, Administration, Oral ; Aminopyridines/therapeutic use ; Animals ; Antineoplastic Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Biomarkers, Tumor/metabolism ; Cell Line, Tumor ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Humans ; Inhibitory Concentration 50 ; Mice, Nude ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/therapeutic use ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays

المؤلفون: Yin T; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Lallena MJ; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Kreklau EL; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Fales KR; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Carballares S; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Torrres R; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Wishart GN; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Ajamie RT; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Cronier DM; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Iversen PW; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Meier TI; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Foreman RT; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Zeckner D; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Sissons SE; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Halstead BW; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Lin AB; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Donoho GP; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Qian Y; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Li S; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Wu S; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Aggarwal A; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Ye XS; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Starling JJ; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., Gaynor RB; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom., de Dios A; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom du_jian@lilly.com de_dios_alfonso@lilly.com., Du J; Authors' Affiliations: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana; Eli Lilly and Company, Alcobendas, Madrid, Spain; and Eli Lilly and Company, Windlesham, United Kingdom du_jian@lilly.com de_dios_alfonso@lilly.com.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2014 Jun; Vol. 13 (6), pp. 1442-56. Date of Electronic Publication: 2014 Mar 31.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Apoptosis/*drug effects , Cyclin-Dependent Kinase 9/*genetics , Cyclohexylamines/*administration & dosage , Indazoles/*administration & dosage , Leukemia/*drug therapy, Cell Line, Tumor ; Cyclin-Dependent Kinase 9/antagonists & inhibitors ; Humans ; Leukemia/pathology ; Myeloid Cell Leukemia Sequence 1 Protein/biosynthesis ; Phosphorylation/drug effects ; Serine/metabolism

المؤلفون: Sheehan SM; Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN 46285, USA. SHEEHAN_SCOTT@LILLY.COM, Mest HJ, Watson BM, Klimkowski VJ, Timm DE, Cauvin A, Parsons SH, Shi Q, Canada EJ, Wiley MR, Ruehter G, Evers B, Petersen S, Blaszczak LC, Pulley SR, Margolis BJ, Wishart GN, Renson B, Hankotius D, Mohr M, Zechel JC, Michael Kalbfleisch J, Dingess-Hammond EA, Boelke A, Weichert AG

المصدر: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2007 Mar 15; Vol. 17 (6), pp. 1765-8. Date of Electronic Publication: 2006 Dec 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0960-894X (Print) Linking ISSN: 0960894X NLM ISO Abbreviation: Bioorg Med Chem Lett Subsets: MEDLINE

مواضيع طبية MeSH: Dipeptidyl-Peptidase IV Inhibitors*, Protease Inhibitors/*chemical synthesis , Protease Inhibitors/*pharmacology, Animals ; Binding Sites ; Computer Simulation ; Crystallography, X-Ray ; Dipeptidyl Peptidase 4/blood ; Drug Evaluation, Preclinical ; Hydrogen Bonding ; Male ; Models, Molecular ; Molecular Conformation ; Protease Inhibitors/chemistry ; Rats ; Rats, Wistar ; Spectrometry, Fluorescence

المؤلفون: French MC, Wishart GN

المصدر: Journal of pharmacological methods [J Pharmacol Methods] 1985 Jun; Vol. 13 (3), pp. 241-8.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier/north-Holland Country of Publication: United States NLM ID: 7806596 Publication Model: Print Cited Medium: Print ISSN: 0160-5402 (Print) Linking ISSN: 01605402 NLM ISO Abbreviation: J Pharmacol Methods Subsets: MEDLINE

مواضيع طبية MeSH: Aerosols/*metabolism , Lung/*physiology , Perfusion/*instrumentation, Absorption ; Anesthesia ; Animals ; Carbon Dioxide/blood ; Hydrogen-Ion Concentration ; In Vitro Techniques ; Models, Biological ; Oxygen/blood ; Rabbits ; Respiration ; Tidal Volume